Asthma is a common condition affecting 8.3% of the adult population in the United States. The disease is characterized by chronic airway inflammation that leads to airway hyperresponsiveness and obstruction that results in coughing, wheezing, shortness of breath, and a feeling of chest tightness. The diagnosis and classification of asthma is based on reported symptoms, physical examination findings, and spirometry. Pharmacologic therapy is prescribed using a stepwise approach that begins with inhaled short-acting beta 2 -agonists for intermittent asthma with the addition of daily inhaled corticosteroids for more persistent cases. Individuals with asthma are reevaluated on a regular basis to monitor symptoms, and pharmacologic treatments are adjusted as needed. Familiarity with the stepwise approach for asthma management and confidence in the efficacy and safety profiles of inhaled medications will assist clinicians in successful management of asthma in the primary care setting. 
C.E., a 24-year-old woman, presented as a new client for a well-woman examination. She reported good health overall but had been experiencing a cough and shortness of breath since moving to Florida 3 months ago. C.E. reported shortness of breath, wheezing, and a sensation of chest tightness 3 to 4 days per week and nighttime awakening with coughing about once a week for the past month. She recently started a new job at a theme park working in a merchandise
The
clinician made a diagnosis of asthma and classified the asthma as mild persistent based on C.E.'s symptoms and lung function. Asthma treatment was initiated at Step 2 of the recommended treatment guidelines, which included

INTRODUCTION
Asthma is a common and costly illness that affects 8.3% of adults in the United States.
1 Asthma symptoms are the reason for 11 million outpatient office visits and 1.7 million emergency department visits annually. 2, 3 Asthma costs are estimated to exceed 80 billion dollars annually in the United States, and the condition is associated with activity limitations, diminished work and school productivity, and reduced quality of life. 4 The National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 (EPR-3) Guidelines for the Diagnosis and Management of Asthma is the preferred guideline for the care of individuals with asthma. 5 The National Heart, Lung, and Blood Institute of the National Institutes of Health established the NAEPP in 1989 by convening a group of experts to develop an evidence-based approach to asthma management in an effort to reduce rising morbidity and mortality from the disease. 6 The first NAEPP Expert Panel Report (EPR-1) was published in 1991. 6 A revision to the guideline, the EPR-2, was released in 1997 with an update on selected topics released in 2002. 6 The most recent version, the EPR-3, was released in 2007; an update to the EPR-3 is currently in process, although the anticipated date for publication is unknown at this time. 6 
PATHOPHYSIOLOGY
The pathophysiology of asthma is complex in nature. The primary feature is airway inflammation caused by ✦ Asthma symptoms are the reason for 11 million outpatient office visits and 1.7 million emergency department visits annually in the United States, and the condition is associated with activity limitations, diminished work and school productivity, and reduced quality of life.
✦ Subjective data collection is particularly important for evaluation of individuals with suspected asthma because the presentation of the disease is highly variable and some individuals present with only symptoms and no abnormal physical examination or spirometry findings.
✦ Pharmacologic management of asthma is based on the classification of asthma severity, and the goals of treatment are to minimize impairment and to reduce the risk of adverse outcomes associated with uncontrolled disease.
✦ The stepwise approach for managing asthma is a method of treating individuals with the understanding that asthma can be intermittent and that symptoms can vary over time.
✦ The use of inhaled corticosteroids is the cornerstone of treatment for persistent asthma as these medications address the underlying pathophysiology responsible for clinical symptoms.
✦ Client education is an important component of providing care for persons with asthma; topics include proper use of inhalers, identification of triggers, and signs of worsening asthma.
✦ Clinicians can feel confident prescribing inhaled corticosteroid and long-acting beta 2 -agonist combination medications knowing that they do not increase the risk of asthma-related death and also appear to reduce the risk of asthma exacerbations when compared with inhaled corticosteroids alone.
inflammatory cells and an immunoglobulin E (IgE)-mediated response to allergens. 7, 8 This chronic inflammation causes airway hyperresponsiveness and airway obstruction, resulting in the clinical symptoms of coughing, wheezing, shortness of breath, and chest tightness. 8, 9 Airflow limitation in persons with asthma is reversible and can occur spontaneously or with treatment. 9 Over time, tissue remodeling occurs in response to chronic inflammation, and these histopathological changes lead to further reduced lung function. 7, 8 Risk factors for childhood and early-adult-onset asthma include genetic and environmental factors. Atopy, the genetic tendency to develop allergic diseases, is the most potent risk factor. 8, [10] [11] [12] Atopy is associated with intense immune responses to common allergens, particularly allergens that are inhaled or ingested. Thus, many individuals with asthma symptoms that began in childhood also have atopic dermatitis (eczema), allergic rhinitis, and/or food allergies. 8, 9 Individuals who develop asthma later in adulthood are more likely to be female or have a history of smoking.
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DIAGNOSIS
Subjective data collection is particularly important for evaluation of individuals with suspected asthma because the presentation of the disease is highly variable and some individuals present with only symptoms and no abnormal findings on physical examination or spirometry. 8, 9 Common symptoms include wheezing, coughing, shortness of breath, and a sensation of chest tightness. 8, 9 Symptoms, particularly the cough, tend to be worse at night or in response to triggers such as exercise, viral infections, allergens, irritants, weather changes, strong emotions, stress, or menstruation. 9, 11 Symptoms are episodic and can be intermittent or variable. 9 Clinicians should inquire about the pattern of symptoms, precipitating factors, and their impact on activities. 11 The individual should also be asked about personal and family history of asthma, allergic rhinitis, or eczema. 8 The physical examination includes assessment of the following: the upper respiratory tract for signs of allergic rhinitis, such as mucosal swelling, rhinorrhea, and nasal polyps; the lungs for wheezing, abnormal accessory muscle usage, and thorax hyperexpansion; and the skin for signs of atopic dermatitis.
8,11
Spirometry
In adults with suspected asthma, spirometry is the most important diagnostic test as it can reveal airway obstruction and will also assess for reversibility when performed before and after bronchodilator administration. 9 Spirometry, which measures airflow during inspiration and expiration, is generally done as an outpatient test in the hospital setting. 13 The most important values when evaluating for asthma are the forced expiratory volume in 1 second (FEV 1 ), which is the amount of air an individual can forcibly exhale in 1 second, the forced vital capacity (FVC), which is the total amount of air exhaled during a forced breath, and the FEV 1 /FVC ratio, which is the amount exhaled in one second divided by the total amount of air that the individual forcibly exhales. 9 The ideal FEV 1 /FVC ratio for an individual is dependent on the age of the person and should be 80% for women aged 20 to 39 years. Reference ranges for all ages are available in the NAEPP guidelines (Table 1) . 11 A reduced FEV 1 /FVC ratio can indicate airway obstruction. 9, 13 The individual is then given a single dose of a short-acting beta 2 -agonist (SABA), such as albuterol, and the test is repeated. 13 If the FEV 1 increases at least 12% and 200 mL of volume after bronchodilator administration, this indicates reversibility of the airway obstruction, which meets the criteria for asthma. Step 1
Step 2
Step 3
Step 4 or 5 The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual needs. Evaluate degree of asthma control in 2-6 weeks and adjust step therapy as needed. Source: National Heart, Lung, and Blood Institute (NHLBI), National Asthma Education and Prevention Program.
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In addition to baseline spirometry completed for the initial diagnosis of asthma, repeat spirometry is used as part of long-term monitoring of the condition. 11 Optimal times to use spirometry include after the individual is initially stabilized; during lengthy periods of uncontrolled symptoms; and, at minimum, every 1 to 2 years. 11 Follow-up spirometry can be particularly helpful in identifying individuals who are at risk for asthma exacerbations.
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Additional Diagnostic Tests
Occasionally, additional diagnostic testing such as chest radiography may be needed to rule out other pulmonary diseases such as lung cancer. 9 Routine chest radiography has not been shown to be helpful in younger adults with no comorbidities. However, if the individual is an older adult, has comorbid conditions, smokes tobacco, or has a history of significant occupational exposures, chest radiography should be performed. 9 For individuals with severe cases of asthma, a complete blood count and serum total IgE to assess for eosinophilia and atopic asthma may also be considered. 
Differential Diagnoses
A diagnosis of asthma is made when the individual has episodic symptoms of airflow obstruction that are at least partially reversible and differential diagnoses can be ruled out. 11 Differential diagnoses for asthma in adults include the following: conditions that cause chronic cough, such as allergic rhinitis, chronic upper airway cough syndrome (postnasal drip), gastroesophageal reflux disorder, and medicationrelated cough; lower respiratory conditions that cause cough or dyspnea, such as interstitial lung disease, chronic obstructive pulmonary disease, alpha-1 antitrypsin deficiency, pulmonary embolism, tuberculosis, lung cancer, and bronchiectasis; and chronic cardiovascular conditions, such as congestive heart failure and pulmonary hypertension. 
INITIAL CLASSIFICATION OF ASTHMA
Asthma is classified as intermittent, mild persistent, moderate persistent, or severe persistent based on the individual's symptoms and spirometry data. Symptoms included in the classification are daytime symptoms, nighttime awakenings, SABA usage (if applicable), and to what degree the symptoms interfere with daily activities (Table 1) . 11 Individuals with intermittent asthma have symptoms 2 or fewer days per week, have no activity impairment, and have nighttime symptoms 2 or fewer nights per month. 11 In contrast, individuals with severe persistent asthma have symptoms throughout the day, are extremely limited in their normal activities, and often awaken every night with symptoms. 11 The NAEPP recommends consultation with an asthma specialist for individuals with symptoms of severe persistent asthma, and these clients may be treated with newer biologic therapies in addition to traditional treatments. 9, 11 Specialty consultation for women with a milder asthma classification may be reasonable depending upon the clinician's scope of practice and resources.
STEPWISE APPROACH FOR MANAGING ASTHMA
Pharmacologic management of asthma is based on the classification of asthma severity. The goals of treatment are twofold: to minimize impairment and to reduce the risk of adverse outcomes associated with uncontrolled disease. Specifically, the goals for minimizing impairment include controlling symptoms and reducing activity limitation. 8, 9, 11 Goals for reducing the risk of adverse outcomes include avoiding exacerbations and the need for emergency care, prevention of loss of lung function, and minimizing adverse effects of therapy. 8, 9, 11 Persons with asthma are at increased risk for complications that result from upper respiratory tract infections. 11 In addition to pharmacologic management, these individuals are encouraged to receive a yearly influenza vaccination. Clinicians should also ensure that adults with asthma are educated about the importance of receiving the pneumococcal polysaccharide vaccine as well as a one-time tetanus, diphtheria, and pertussis vaccination. 17 The stepwise approach for managing asthma is a method of treating individuals with the understanding that asthma can be intermittent and that symptoms can vary over time. In order to use the least amount of medication necessary, individuals are frequently reevaluated to step up therapy as needed and to step down if symptoms remain controlled for several months.
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Step One
Adults with intermittent asthma begin with Step 1 therapy, which includes an inhaled SABA such as albuterol to use every 4 to 6 hours as needed for asthma symptoms (Table 2) . 11 SABAs relax the smooth muscle of the airways by stimulating beta 2 adrenergic receptors. 18 The onset of action of albuterol is within 5 minutes, and the half-life of the medication is between 4 and 6 hours with a peak effect between 30 and 60 minutes. 18 Most albuterol inhalers are metered dose inhalers (MDIs). MDIs dispense the active ingredient by suspending the medication in a propellant and then delivering it through a pressurized aerosol device. 19 Because of environmental concerns, in 2008, the US Food and Drug Administration (FDA) banned the sale of albuterol MDIs that used chlorofluorocarbons to propel the medication into the lungs. 20 Current albuterol MDIs, which include brand names ProAir, Proventil, and Ventolin, are only available as hydrofluoroalkane (HFA) propelled inhalers, 20 and the abbreviation HFA is often noted on the prescription. When using MDIs, the addition of a spacer can be helpful, even for adults, to ensure that a maximum amount of medication is delivered into the lungs. 9 A spacer reduces the need for coordination between pressing the canister and inhaling.
If an individual is using the prescribed SABA inhaler more than 2 days per week for asthma symptoms, this is an indication that the person has persistent asthma and that the treatment plan needs to be stepped up.
Step Two
The use of inhaled corticosteroids is the cornerstone of treatment for persistent asthma as these medications address the underlying pathophysiology responsible for clinical symptoms. These agents improve lung function, reduce asthma symptoms, and lower the risk for exacerbations. 9 Individuals with mild persistent asthma begin treatment with
Step 2 therapy that adds the use of a low-dose inhaled corticosteroid (Table 2) . 11 Although the full mechanism of action to reduce inflammation is not known, inhaled corticosteroids inhibit multiple inflammatory genes. 21 The available inhaled corticosteroids (Table 3 ) are effective and have minimal side effects at low and medium doses. 22 A recent systematic review by Yeo and colleagues found that there were no significant differences in client outcomes between different agents in the majority of randomized controlled trials comparing various inhaled corticosteroids. 23 Inhaled corticosteroid choice can be determined based on cost, availability, and client preference. 19 Various inhaled corticosteroids are available as MDIs, as dry powdered inhalers (DPIs), or both. 19 To administer a DPI, the individual uses the device to slice a blister containing the active ingredient and then draws in the powdered medication with a deep breath. 19 DPIs do not have a propellant, so it is important that the individual inhale forcefully and deeply and to remember not to exhale into the device prior to administration of the drug. 19 After taking an inhaled corticosteroid, either by MDI or DPI, it is also important that the individual rinse out the mouth to avoid development of oral candidiasis.
Step Three
Persons with moderate persistent asthma begin at Step 3, which may include either the use of a medium-dose inhaled corticosteroid or, alternatively, the use of a low-dose inhaled corticosteroid in combination with a long-acting beta 2 -agonist (LABA; Table 2 ). 11 LABAs have the same mechanism of action as SABAs, but they have a longer half-life, with sustained activity for at least 12 hours. 18 LABAs historically have been avoided when possible because of a reported increased risk of asthma-related death associated with their use; however, these initial studies were performed with individuals who may not have also been using an inhaled corticosteroid. 24 More recent studies have not found an increased risk of asthma-related death when LABAs are used in combination with inhaled corticosteroids, and in December 2017, the FDA removed the asthma-related black box warning from the combination medications. 24 Busse and colleagues also examined the outcomes from the 4 large clinical trials reviewed by the FDA and concluded that, additionally, individuals using LABAs in combination with inhaled corticosteroids had a lower risk of asthma exacerbation when compared with individuals taking inhaled corticosteroids alone. 25 There is evidence that when inhaled Step 1
Preferred: SABA as needed
Preferred: Low-dose ICS Alternative a,b
Preferred: Low-dose ICS + LABA or medium-dose ICS Alternative a,c
Step 4 corticosteroids and LABAs are used together, the beneficial effects of both medications are enhanced. 21 Although either option is acceptable, newer evidence suggests that individuals may have improved symptom control and better tolerability with a low-dose inhaled corticosteroid combined with a LABA when compared with the medium-dose inhaled corticosteroid treatment option for Step 3. Step Four
Consultation with an asthma specialist is recommended for individuals needing Step 4 therapy, which includes combination therapy with a medium-dose inhaled corticosteroid and a LABA (Table 2) , and for individuals who have been hospitalized or those who have required the use of 2 courses of oral steroids within the last year. 9, 11 Immediate referral to the nearest emergency department is required for individuals who are drowsy or confused or have diminished or absent breath sounds. 8 
CLIENT EDUCATION
Client education is an important component of providing care for persons with asthma. Topics include proper use of inhalers, identification of triggers, and signs of worsening asthma. It is imperative that clinicians instruct individuals on proper inhaler use, both on administration technique and on the importance of adhering to the recommended therapy. Poor adherence to daily controller medications and overuse of SABAs have been linked to severe asthma exacerbations and asthma-related death. 8 Incorrect inhaler technique is a common problem that increases the risk for asthma exacerbations and overall poor asthma control. 8, 19 A recent metaanalysis by Chrysten et al revealed that between 50% and 100% of adults using inhaler devices experience at least one error when self-administering inhaled medications. 26 Melani et al revealed through a recent large study that the most common error for both MDI and DPI administration is insufficient duration of holding one's breath after inhalation, and inhaler misuse was strongly associated with lack of instruction from the health care team. 27 Clinicians should demonstrate inhaler technique and reinforce this skill at every opportunity. 19 Axtell et al found that a short counseling session with a clinician is more effective in educating individuals on correct inhaler usage than other interventions, such as videos or reading materials. 28 Basheti et al found that reminder labels placed on the inhalation devices that include steps for administration were also helpful in reducing errors. 29 Clinicians should also work to identify precipitating factors of symptoms so that individuals can reduce exposure to allergens and irritants when possible. 11 Encouraging smoking cessation and avoidance of exposure to tobacco smoke is an essential component of education as tobacco smoke has been linked to asthma exacerbations. 9 Additionally, clinicians can educate individuals about how allergens in the home can affect asthma symptom frequency and severity and that asthma symptoms can be improved with efforts to reduce exposures to cockroach, rodent, and dust-mite allergens. 11 Clinicians may consider a referral for allergy testing to assist with allergenavoidance methods. 9 It is also critical that clinicians deliver education on recognition of early signs and symptoms of worsening asthma. 8 Individuals should be provided with and instructed on use of a home peak flow meter, and a written asthma action plan that includes information on when to seek medical care should be developed in collaboration with the client.
8,11,30-32 Peak flow meters measure how much air an individual can expel out of the lungs in one fast blast of breath. 33 Individuals blow into the device to determine their personal best and then use that number to compare future results. 33 Although studies have not confirmed that a personalized, written asthma action plan improves asthma outcomes compared with verbal education from the clinician alone, asthma experts recommend the use of asthma action plans. Many institutions have adopted asthma plans, and templates can be found on several internet sites. 
REASSESSING ASTHMA CONTROL
Persons with asthma should be reassessed 2 to 6 weeks after initiating or adjusting therapy. 11 The effectiveness of asthma control is determined, similarly to how it is initially classified, using reported daytime symptoms, nighttime awakenings, SABA usage, and to what degree the symptoms interfere with daily activities (Table 4) . 11 Although a peak flow meter should not be used as a replacement of spirometry testing for diagnosis of asthma, it is a helpful tool that can be used in the clinic setting to assess asthma control. 11 Asthma is generally considered to be well controlled if the peak flow is at least 80% of the individual's personal best, but a peak flow reading is only part of the person's clinical picture of asthma control. 11, 33 For individuals in whom asthma is deemed well controlled, continuation of the current treatment plan and followup every 1 to 6 months is recommended, with a possible step down in the treatment plan being considered after 3 months for individuals taking daily controller medicines. 11 In individuals for whom asthma is not well controlled, treatment is stepped up one step and then reevaluated again in 2 to 6 weeks, and in persons for whom asthma is very poorly controlled, clinicians may consider a short course of oral corticosteroids and then will step up the treatment plan by 1 to 2 steps with a reevaluation in 2 weeks (Table 4) .
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ASTHMA EXACERBATIONS
Asthma exacerbations are acute or subacute episodes of worsening asthma symptoms that require a change in treatment. 8 Exacerbations occur most often when the individual develops a respiratory viral infection but may also occur after exposure to allergens, irritants, or other environmental triggers.
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A history of prior exacerbations is a well-established risk factor for future asthma exacerbations. 34 Exposure to outdoor air pollutants has been linked to moderate to severe asthma exacerbations as well as emergency department visits and hospitalizations. 35, 36 Occupational exposures are an added potential hazard for adults with asthma. For example, Henneberger et al found that adults who had occupational exposures to dust, gas, or fumes were more likely to have severe asthma exacerbations. 37 Mazurek et al found that adults who manufacture wood, plastic, and rubber products are at increased risk for asthma exacerbations. 38 Mild exacerbations, in which symptoms may be noted with physical exertion and the individual's peak flow is above or equal to 70% of his or her personal best, generally require an increased use of a SABA. 39 Moderate exacerbations are commonly seen in the primary care setting; peak flow is 40% to 69% of the individual's personal best, and symptoms interfere with daily activities. 39 In addition to increased use of SABAs, these individuals benefit from a course of oral corticosteroids. 39 For adults with severe exacerbations who present with dyspnea at rest and a peak flow under 40% of their personal best, evaluation in an emergency department and potential hospitalization may be required. 39 Individuals with life-threatening exacerbations are too short of breath to speak and require immediate medical transport to the nearest emergency department. 
IMPLICATIONS FOR CLINICAL PRACTICE
Asthma is more common in women, and asthma in women is often more severe than in men and may not respond as d Consider severity and interval since last exacerbation. At present there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or intensive care unit admission) indicate poorer disease control. For treatment purposes, individuals who had ࣙ2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as individuals who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma. e The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual needs. Before stepping up therapy: review adherence to medication, inhaler technique, environmental control, and comorbid conditions, and if an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step. Source: National Heart, Lung, and Blood Institute (NHLBI), National Asthma Education and Prevention Program. well to treatment. 12 Nurse-midwives and other clinicians who care for women can successfully treat asthma in the primary care setting using the NAEPP guidelines. Clinicians can feel confident prescribing inhaled corticosteroid/LABA combination medications knowing that they do not increase the risk of asthma-related death and also appear to reduce the risk of asthma exacerbations when compared with inhaled corticosteroids alone. 18, 40, 41 As clinicians become more skillful in treating asthma in the primary care setting, asthma-specialist referrals can be reserved for individuals with severe asthma. Emerging therapies for clients with severe asthma not controlled with traditional therapies include the use of longacting muscarinic agonists such as tiotropium (Spiriva), immunotherapies, and biologic agents such as omalizumab (Xolair), mepolizumab (Nucala), and reslizumab (Cinqair).
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CONCLUSION
Asthma is a complex illness, and its diagnosis and management can be challenging. However, familiarity with the stepwise approach for asthma management and confidence in the efficacy and safety profiles of inhaled medications will assist clinicians in successfully managing asthma in the primary care setting. The overarching goals of asthma treatment include symptom control, reduction in activity limitation, avoidance of exacerbations, and improvement in quality of life. 8, 9 When caring for women with asthma, it is important to recognize the intermittent and variable nature of the disease and to understand the need for careful follow-up at regular intervals to reevaluate symptoms, to reinforce teaching, and to alter medication therapy as needed.
